Analyst Joseph Schwartz from Leerink Partners maintained a Buy rating on Edgewise Therapeutics (EWTX – Research Report) and increased the price target to $44.00 from $42.00. Joseph Schwartz’s rating ...
RBC Capital analyst Leonid Timashev assigned a Buy rating to Edgewise Therapeutics (EWTX – Research Report) yesterday and set a price target of $42.00. The company’s shares closed yesterday at $35.43.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback